^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Esophageal and Esophagogastric Junction cancer...Trastuzumab should be added to first-line chemotherapy in combination with a fluoropyrimidine and a platinum agent (category 1 in combination with cisplatin; category 2A in combination with other platinum agents) in patients with HER2-positive disease....
Secondary therapy:
cisplatin
Source:
Title:
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Excerpt:
HER2-positive metastatic AC should be treated with a trastuzumab-containing treatment.
DOI:
10.1093/annonc/mdw329
Source:
Title:
133P - HER2 transcription status of diverse solid tumours with clinical implications
Published date:
09/14/2020
Excerpt:
We identified 7 pts that were given Anti-HER2 therapy (Tx). One pt with CNV+/mRNA+/IHC+ metastatic esophageal CA achieved complete response with chemotherapy plus trastuzumab followed by trastuzumab maintenance (progression-free survival [PFS]: 48 + months).
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: C1 - Off-label
(Approved for Gastroesophageal Junction Adenocarcinoma)
New
Excerpt:
Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease.
Source:
Title:
Real-World (RW) United States (US) First-Line (1L) Treatment (TX) Patterns and Overall Survival (OS) of Patients (PTS) with Unresectable Advanced or Metastatic (ADV/MET) Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenoc
Published date:
04/22/2022
Excerpt:
...clinical characteristics and 1L tx were described by HER2 status for adult pts diagnosed with adv/met GC/GEJC/EAC from January 2011 to December 2020...a majority (65%) of HER2+ pts received trastuzumab…. Median OS for HER2+, HER2− and HER2un pts was 12.2, 9.8 and 7.6 months, respectively.
